Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cymerus MSCs show synergy with dexamethasone
February 2018
SHARING OPTIONS:

MELBOURNE, Australia—Cynata Therapeutics Limited recently announced the receipt of the final report on the effects of Cymerus MSCs in combination with or in comparison to dexamethasone in a preclinical asthma study. Daily administration of the drug resulted in significant anti-inflammatory effects in a mouse model. The corticosteroid reduced airway inflammation by 55 percent and airway inflammation-induced goblet cell metaplasia by roughly 80 percent. It showed only weak anti-remodeling and anti-fibrotic effects, however, and reduced airway hyperresponsiveness by only about 30 percent. Once-weekly dosing of Cymerus MSCs, however, led to marked reductions in airway remodeling, fibrosis and airway hyperresponsiveness (70 to 75 percent). The drug also normalized subepithelial collagen deposition and airway TGF-β1 expression levels equivalent to mice that had not been induced with asthma. Together the treatments demonstrated a synergistic effect that featured the anti-inflammatory effects of dexamethasone alone and the reductions seen with Cymerus MSCs alone.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.